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Abstract
Background: Obesity is associated with a relative deficiency of growth hormone, which is predictive of greater
visceral fat and markers of cardiovascular risk. The study’s purpose was to use recombinant human growth
hormone (rhGH) as a physiologic probe to assess the effects of reversing obesity-related GH deficiency on body
composition, cardiovascular risk markers, and insulin resistance.
Methods: 22 obese girls 13–21 years old were followed for a randomized 6-month trial of rhGH vs. placebo/no
treatment. At baseline and 6-months, DXA was performed for body composition, MRI to measure visceral, subcutaneous
and total adipose tissue (VAT, SAT and TAT), and fasting blood drawn for IGF-1, inflammatory cardiovascular risk markers
[soluble intercellular adhesion molecule (sICAM), high sensitivity CRP], lipids and HbA1C. An oral glucose tolerance test
(OGTT) was performed. Twelve girls completed the 6-month visit. Baseline and mean 6-month change were compared
between the groups using the Student t-test and the relationship between variables was determined through multiple
regression analysis.
Results: After 6-months, the rhGH group maintained IGF-1 levels, and had decreases in total cholesterol (p=0.03),
sICAM-1 (p=0.04) and HbA1C (p=0.03) compared to placebo/no treatment. The rhGH group trended towards greater
decreases in LDL and 2-hour OGTT glucose. Glucose tolerance did not worsen with rhGH administration.
Conclusions: Administering rhGH in small doses is able to stabilize IGF-1 levels in obesity. We have also shown that
rhGH administration leads to an improvement in some markers of cardiovacular risk with without adversely affecting
glucose tolerance.
Trial registration: Clinical Trial Registration Number: NCT01169103.
Keywords: Adolescents, Growth hormone, Visceral fat, Body composition, Females, Inflammatory markers
Background
Obesity, a pressing global issue, is characterized by
diminished growth hormone (GH) secretion in adults
[1,2] and adolescents [3], with decreased frequency and
amplitude of GH secretory bursts [4]. Pathological GH
deficiency is characterized by a high risk cardiovascular
profile [5-8], and similarly, in obese individuals, relatively
low GH levels are associated with higher visceral fat [3],
which in turn predisposes individuals to components of
the metabolic syndrome [9,10], including hyperlipidemia
[10,11] and insulin resistance [10,12]. While GH replace-
ment in children with pathologic GH deficiency causes a
decrease in visceral adiposity [13], effects of GH admin-
istration on body composition have not been examined
in an otherwise healthy adolescent obese population that
is relatively GH insufficient.
Existing studies examining the effects of rh(GH) on
obesity and cardiovascular risk factors have largely been
performed either on adults or in children with specific
chronic health conditions such as GH deficiency [13] or
Prader-Willi Syndrome [14]. Consequently, there is a
dearth of data regarding effects of GH replacement on
body composition and cardiometabolic risk in otherwise
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used rhGH as a physiologic probe to observe the effects
of GH replacement on body composition. We hypothe-
sized that rhGH administration in replacement doses to
obese adolescent females would have lipolytic effects
without deleterious effects on glucose tolerance.
Methods
The study was approved by the Institutional Review
Board of Partners HealthCare system. Written informed
consent (for patients ≥18 years) or parental consent with
participant assent (for patients <18 years) was obtained
from all.
Subject selection
Participants were recruited at Massachusetts General
Hospital (MGH) between September 2010 and October
2012 through area pediatric and obesity clinics. Of 32
girls and young women 13–21 years old assessed for study
eligibility, 22 obese adolescents met inclusion criteria and
were randomized. Inclusion criteria comprised (i) a bone
age ≥14 years, (ii) body mass index (BMI)>95th percent-
ile for age (based on the 2000 Centers for Disease Control
and Prevention Growth Charts) [15], or >30 kg/m
2 if age
>18 years, (iii) insulin like growth factor-1 (IGF-1) level
below the median for pubertal stage or age, (iv) abdominal
obesity with a waist to hip ratio (W/H) >0.85, and (v)
stable weight (<5 kg change in weight in the prior
3 months). Exclusion criteria included diabetes mellitus,
untreated thyroid dysfunction, chronic renal insufficiency,
current or past malignancy, syndromic obesity, pregnancy,
breast-feeding, and use of medications known to alter
glucose metabolism or body composition (contraceptive
pills, daily glucocorticoid use, metformin, sibutramine and
Orlistat). Additionally, we excluded girls with new
(<6 months) or unstable dosing (dosage change within 3-
months) of antipsychotic medications known to cause
weight gain. Baseline characteristics for a subset of study
participants have been previously published [16].
Eleven subjects were randomized to active rhGH treat-
ment {rhGH (+)} and 11 to rhGH negative {rhGH (−)}
treatment. Sixteen subjects {10 rhGH (+) and 6 rhGH (−)}
completed the 3-month visit, and 12 subjects {5 rhGH (+)
and 7 rhGH (−)} finished the 6-month study period (one
rhGH (−) subject missed the 3-month visit but completed
other visits). No subject dropped out because of side
effects. Of subjects who withdrew (n=10), one chose to
begin an oral contraceptive, 3 withdrew because of
personal obligations, and the remaining were considered
lost to follow-up (n=6). Study participants who did or did
not complete the study did not differ for baseline
characteristics.
Experimental protocol
The study was a 6-month, single-blind, randomized trial,
conducted at the Clinical Research Center of MGH. The
screening visit included a history and physical examination
and blood sampling to ensure participants met inclusion
criteria and to rule out exclusion criteria. Diabetes was
ruled out via an oral glucose tolerance test (OGTT).
Eligible subjects returned for the baseline visit, visits at 1
and 2 weeks (for dose adjustment), and at 1, 3 and 6 months.
Subjects were randomized 1:1 to receive once daily subcuta-
neous rhGH or placebo injections (Somatropin, Genentech,
Inc., San Francisco, CA, USA), and taught to self inject
medication daily for 6-months. Due to non-availability of
placebo (and inability for new placebo to be manufactured)
after June 2012, subjects subsequently randomized to pla-
cebo (n=4) were instead randomized to no treatment. Die-
ticians and the radiologist who performed study related
procedures as well as all subjects who enrolled prior to June
2012 (N= 15) remained blinded to randomization status for
the entirety of the study. After the placebo expiration
necessitated the change in the study design, one subject
randomized to rhGH (+) subject and one subject ran-
domized to rhGH (−) treatment dropped out. The sub-
ject randomized to rhGH (−) treatment withdrew due
to the initiation of an oral contraceptive while the sub-
ject randomized to rhGH (+) was lost to follow up after
the 3 month visit.
T h es t a r t i n gr h G Hd o s ew a s0 . 4m ga n di n c r e a s e da t
week-1 and week-2 to 0.6 mg and 0.8 mg respectively.
T h ed o s i n gw a sb a s e do nad o s eo f1 2 . 5m c g / k g / d a y
for a 16-year-old girl (mean for bone ages 14–18
years) weighing 67 kg (85th percentile for age) [17].
This dosage (0.8 mg at week-2) is at the lower end of
the 12.5–25 mcg/kg/day dose used in studies of GH de-
ficient adolescents transitioning from pediatric (40–45
mcg/kg/day) to adult (2–6 mcg/kg/day) replacement
rhGH doses [17,18]. We opted for this lower dose as
we expected lower GH requirements in this population
that is relatively, rather than completely, GH insufficient.
The dose was adjusted as needed by 20% at the 1 and
3-month visits to achieve IGF-1 levels in the upper half of
the normal range for pubertal stage. When target IGF-1
was achieved, the individualized dose was continued.
Study procedures
Height was measured as the average of three measurements
to the nearest 0.1 cm on a single calibrated wall-mounted
stadiometer. Participants, wearing a hospital gown, were
weighed to the nearest 0.1 kg on a single calibrated elec-
tronic scale. BMI was calculated as weight (in kg) divided
by height (in meters
2)a n dB M Is t a n d a r dd e v i a t i o ns c o r e s
(SDS) determined from 2000 CDC charts [15]. Waist mea-
surements were taken with a plastic tape measure to the
nearest 0.1 cm at the level of the iliac crest and umbilicus;
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measurements were taken at the end of expiration with the
subject standing. Waist-to-hip ratio (W/H) was calculated
as the iliac divided by the hip circumference measurement.
An ophthalmoscope was used to rule out papilledema at
study onset, and at the 3 and 6-month visits, or if any
subject complained of headaches, vision changes, nausea or
vomiting. Subjects had a left hand x-ray to assess bone age
[19]. Pubertal stage was determined according to the
criteria of Tanner [20].
Magnetic resonance imaging (MRI) at the level of L4
was used to determine visceral adipose tissue (VAT) and
subcutaneous adipose tissue (SAT) at baseline and
6 months; total abdominal adipose tissue (TAT) was calcu-
lated as VAT+ SAT [21]. MRI data are available for 11
completers (due to scheduling conflicts one no-treatment
subject was unable to perform the MRI component). Body
composition was also obtained by dual energy x-ray ab-
sorptiometry scans (DXA) at the baseline, 3 and 6-month
visits. DXA (Hologic QDR-Discovery A; Hologic Inc.,
Waltham, MA software version APEX 3.3) was used to
assess percent body fat, total, trunk and extremity fat and
total and extremity lean mass.
Subjects met with nutritionists of the Clinical Research
Center at the baseline, 3 and 6-month visits for (i) basic
lifestyle counseling including healthy eating habits and
optimizing exercise, and (ii) assessment of prior activity
using the Modified Activity Questionnaire (MAQ) [22].
To avoid confounding variables, further dietary or exercise
restrictions were not imposed.
Fasting blood samples were drawn for IGF-1 at each
visit for rhGH dose adjustment, and a 75-g, 2-hour
OGTT performed at screen, 3 and 6-months to determine
whether rhGH administration had deleterious effects on
glucose tolerance. Fasting blood samples were also
assessed for cardiovascular risk markers [lipids, high sensi-
tivity C-reactive protein (hs-CRP), soluble intercellular
adhesion molecule-1 (sICAM-1)], HbA1C, glucose and
insulin levels at baseline and 6-months.
IGF-1 was analyzed by enzyme-linked immunosorbent
assay (ELISA) (Immunodiagnostic systems, Scottsdale,
AZ; Limit of Detection (LOD) 3.1 ng/mL, CV <7%).
Fasting insulin was analyzed by immunoassay (Cobas,
Roche Diagnostics, Indianapolis, IN; LOD 0.2 μU/mL, CV
0.8 to 4.9%), glucose via an enzymatic in vitro test (Cobas,
Roche Diagnostics, Indianapolis, IN; LOD 2 mg/dL, intra-
assay CV 1.0%), total cholesterol, LDL and HDL via a
Roche direct assay (Cobas, Roche Diagnostics, Indianapo-
lis, IN) [total cholesterol (LOD 3 mg/dL, CV 0.8–1.0%),
LDL (LOD 3 mg/dL, intra-assay CV 0.71–1.22%) and
HDL (LOD 3 mg/dL, intra-assay CV 0.60–0.95%)], triglyc-
erides via the Roche triglyceride assay (Cobas, Roche
Diagnostics, Indianapolis, IN; LOD 4 mg/dL, intra-assay
CV 0.9–1.5%), and VLDL calculated by subtracting LDL
and HDL from total cholesterol. sICAM-1 was analyzed
by ELISA (RnD Systems, Minneapolis, MN; minimum de-
tectable concentration 1 ng/mL, CV<8%), hsCRP via an
immunoradiometric assay (IRMA) (LabCorp, Burlington,
NC; LOD 0.3 mg/L, intra-assay CV<10%). ALT was
analyzed by the Architect assay (Abbott, Abbott Park, IL;
LOD 2.0 U/L, intra-assay CV<5.2%). Serum was stored
at −80°C for insulin, ALT, and cardiovascular risk factors
until analysis. Other samples were analyzed in real time.
Statistical methods
JMP Software (v10: SAS Institute, Inc., Cary, NC) was
used for analysis. Results are reported as means±SD.
Table 1 Baseline characteristics of all obese adolescent
girls at study entry
RhGH +
N=11
RhGH -
N=11
P
Age (years) 16.2±2.6 16.9±2.2 0.50
Bone age (years) 16.9±1.2 17.2±1.3 0.56
Weight (kg) 104.7± 24.8 97.4±15.4 0.42
BMI (kg/m
2) 40.4±8.4 36.6±6.4 0.25*
BMI SDS 2.3± 0.4 2.1± 0.4 0.22
Waist circumference (cm) 119.4± 17.1 115.0±14.8 0.53
W/H ratio 0.95±0.06 0.93±0.08 0.62
SAT (cm
2) 615.6± 175.0 580.0±176.9 (N=9) 0.66
VAT (cm
2) 90.6±35.3 87.1±31.8 (N=9) 0.82
TAT (cm
2) 706.2± 203.5 667.2±179.8 (N=9) 0.66
Thigh subcutaneous
fat (cm
2)
224.2± 69.4 221.4±96.3 0.95
Lean mass (grams) 54353± 9719 52276±6842 0.57
IGF-1 (ng/mL) 250.6± 129.9 271.8±73.1 0.64
2 HR glucose
(OGTT) (mg/dL)
107.1± 20.5 114.0±18.5 0.42
HbA1c (%) 5.78±0.30 5.49±0.30 0.03
Insulin uU/mL 26.4±21.3 40.1±37.2 0.29*
Total cholesterol (mg/dL) 167.6± 38.3 156.0±33.5 0.46
LDL (mg/dL) 103.8± 28.8 92.6±30.1 0.33*
HDL (mg/dL) 45.1±9.4 43.3±8.5 0.64
VLDL (mg/dL) 18.6±9.4 20.1±8.0 0.70
Triglycerides (mg/dL) 93.0±47.0 100.6±39.8 0.69
hsCRP (mg/L) 4.47±2.76 3.41±3.29 0.25*
sICAM-1 (ng/mL) 268.7± 72.5 220.9±56.4 0.10
*P value reported for log transformed values.
RhGH+: Group that received rhGH; RhGH-: Group that received
placebo/no treatment.
Abbreviations: BMI body mass index, BMI SDS body mass index standard
deviation score, HbA1c hemoglobin A1c, HDL high density lipoprotein, hsCRP
high sensitivity C-reactive protein, IGF-1 insulin like growth factor-1, LDL low
density lipoprotein, OGTT oral glucose tolerance test, SAT subcutaneous
adipose tissue, sICAM-1 soluble intercellular adhesion molecule 1, TAT, VAT
total, visceral adipose tissue, VLDL very low density lipoprotein, W/H waist to
hip ratio.
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using the Student t-test or Wilcoxon rank sum test
depending on data distribution. A paired t-test was also
used to compare baseline and 6 month values within
groups. Parametric (Pearson) or nonparametric (Spear-
man) correlations were used as appropriate to determine
associations between variables that were or were not
normally distributed. Significance was defined as a
two-tailed p-value of <0.05. Multivariate regression
models were constructed to determine whether signifi-
cances for changes in endpoints persisted after control-
ling for weight changes or baseline values of the
endpoint (i.e. HbA1c).
Results
Baseline characteristics
Baseline characteristics are summarized in Table 1. Study
participants had a mean age of 16.6±2.4 years, mean
weight of 100.1±20.5 kg, and a mean BMI of 38.5±
7.5 kg/m
2. Treatment groups did not differ for baseline
characteristics except for a slightly lower HbA1C in the
rhGH (−) group. There were no significant baseline
differences noted between the blinded (N=15) and
unblinded (N=7) groups with one exception; the W/H ra-
tio was higher in the group who remained blinded to their
treatment allocation (0.96±0.06 vs. 0.90±0.07, p=0.05).
All subjects were Tanner Stage V for breast development
at the baseline visit.
Six-month changes in nutritional measures
No differences were noted between rhGH(+) and rhGH(−)
groups for changes in calories consumed (142.6± 961.0 vs.
193.5± 644.0 kcal, p = 0.93), percentage of calories from fat
(−8.09± 12.04 vs. 0.09± 12.95%, p= 0.36), or activity levels
(1.64 ±6.4 vs. 8.83± 9.48 hours/week, p = 0.18).
Table 2 Baseline, 6-month and change in body composition and biochemical parameters over 6-months for study completers
RhGH + RhGH -
Baseline 6-month
N=5
6-month delta Baseline 6-month
N=7
6-month
delta
6 month
delta P
Weight (kg) 99.9±29.5 100.6± 30.9 0.7±4.3 96.5± 18.1 100.4± 23.1 3.9±6.6 0.81*
BMI (kg/m
2) 39.6±10.2 39.8±10.8 0.2±2.0 36.4±7.3 37.8± 9.6 1.4±2.5 0.81*
Waist circumference (cm) 115.4± 21.7 113.7± 23.1 −1.7±4.0 112.4±17.0 112.5± 21.2 0.1±6.5 0.60
W/H ratio 0.94±0.06 0.95±0.06 0.003±0.03 0.91± 0.08 0.91±0.08 −0.005± 0.04 0.72
SAT (cm
2) 578.5±234.8 577.4±232.9 −1.1±60.8 570.0± 206.4 606.3±231.1 36.3± 51.6 (N= 6) 0.30
VAT (cm
2) 92.7±36.6 93.3±47.3 0.6± 29.9 90.4± 39.6 98.4±43.5 8.0 ±31.9 (N=6) 0.70
TAT (cm
2) 671.3±264.1 670.7±278.9 −0.5±83.3 660.3± 209.1 704.6±234.5 44.3± 63.1 (N= 6) 0.34
Thigh subcutaneous fat (cm
2) 217.7± 72.1 208.7± 73.1 −9.0±16.0 228.5± 103.4 211.2± 72.7 18.6± 29.0 (N= 6) 0.08*
Lean mass (grams) 50741.3± 7963.2 50758.1± 8735.6 17±2160 50659.5±7149.8 51360.7± 7309.6 701± 2325 0.62
IGF-1 (ng/mL) 235.4± 61.9 234.0± 48.5 −1.4±79.4 266.0±83.6 185.9± 58.0 −80.1±48.8 0.06
2 HR-glucose (OGTT) (mg/dL) 119.8± 14.8 113.2± 17.6 −6.6±17.0 112.7±14.2 135.1± 23.7 22.4±28.8 0.07
HbA1c (%) 5.62±0.30 5.58±0.16 −0.04±0.17 5.47± 0.25 5.61±0.30 0.14±0.08 0.03
Insulin uU/mL 25.4±25.7 22.6±17.8 −2.8±11.7 41.9± 41.0 27.1±22.5 −14.8±38.3 0.94*
Total cholesterol (mg/dL) 189.2± 42.6 151.4± 27.8 −37.8±23.9 162.1±39.7 153.6± 34.8 −8.6±15.5 0.03
LDL (mg/dL) 121.2± 27.7 95.4±22.4 −25.8±12.8 98.3± 35.8 87.6±28.0 −10.7±11.9 0.06
HDL (mg/dL) 48.2±13.4 41.6± 8.2 −6.6±6.1 44.0±7.4 45.0± 5.2 1.0±5.1 0.04
VLDL (mg/dL) 19.8±11.2 14.4± 6.0 −5.4±9.6 19.9±7.0 21.0±16.3 1.1± 11.7 0.48*
Triglycerides (mg/dL) 99.4±55.7 71.6±29.5 −27.8±46.8 99.1± 35.5 105.3± 24.9 6.1± 58.4 0.57*
hsCRP (mg/L) 3.5±2.1 2.69± 1.8 −0.77±2.36 4.4± 3.8 4.27± 4.6 −0.09±1.79 0.58
sICAM-1 (ng/mL) 226.4± 79.3 204.2± 74.5 −22.2±30.3 241.1±48.1 262.2± 74.8 21.1±33.3 0.04
*Wilcoxon rank sum test.
HbA1c, Total Cholesterol, HDL and sICAM were lower after 6 months of rhGH + treatment.
RhGH+: Group that received rhGH; RhGH-: Group that received placebo/no treatment.
Baseline: Mean Baseline values only for study completers.
6-month: Mean 6-month values for study completers.
6-month delta: Change over 6-months from Mean Baseline to Mean 6-month values.
Abbreviations: BMI body mass index, BMI SDS body mass index standard deviation score, HbA1c hemoglobin A1c, HDL high density lipoprotein, hsCRP high
sensitivity C-reactive protein, IGF-1 insulin like growth factor-1, LDL low density lipoprotein, OGTT oral glucose tolerance test, SAT subcutaneous adipose tissue,
sICAM-1 soluble intercellular adhesion molecule 1, TAT, VAT total, visceral adipose tissue, VLDL very low density lipoprotein, W/H waist to hip ratio.
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Changes in IGF-1 trended higher in the treatment group
(Table 2). At the 6-month visit, mean IGF-1 in the rhGH
(+) group was non-significantly higher than in the rhGH
(−) group (234±24.3 vs. 185.6±20.5 ng/mL, p=0.16).
Six-month changes in body composition
Body composition changes across treatment groups are
presented in Table 2. Although changes in waist circumfer-
ence and W/H ratio did not differ across groups over the
study duration, the increase in IGF-1 between 3–6m o n t h s
correlated with the decrease in W/H ratio over 6-months
(r =−0.74 p =0.009). A similar finding was also seen in the
negative correlation between change in IGF-1 over 3-
months and change in body fat percentage over 3-months
(r =−0.65 p =0.009) (Figure 1). SAT and TAT decreased
non-significantly in the treatment group compared to an
increase in the control group, and VATshowed a negligible
increase compared to the control group.
Six-month changes in cardiovascular risk markers
Lipid levels
At 6-months, subjects in the active group had significant
reductions in total cholesterol compared with controls
(Table 2), and trended to have greater reductions in
LDL. The treatment group also had a greater decrease in
HDL compared with controls. Six-month changes in
IGF-1 correlated negatively with changes in total
cholesterol (r=−0.60, p=0.04) (Figure 2), VLDL (Spear-
man rho =−0.58, p=0.05), and triglycerides (Spearman
rho=−0.67, p=0.02) but not HDL (r=−0.37, p=0.24).
Markers of inflammation
Subjects in the treatment group had a significant decrease
in sICAM-1 (a marker of inflammation) compared to an
increase in controls (Table 2 and Figure 3). Mean changes
in hsCRP did not differ across groups. Additionally, there
was a trend for GH to decrease ALT, a marker of liver in-
flammation, (−5±5 vs. 3±11 U/L, p=0.18 for a 2-tailed
test and 0.0478 for a one-tailed test).
Six-month changes in glycemic status
At 6-months, subjects in the active group had significant
reductions in HbA1c compared to controls (Table 2). This
reduction trended to remain significant after controlling
for baseline HbA1C (p=0.06). Subjects in the active
group also trended to have greater reductions in 2-hour
glucose levels on the OGTT (Table 2). No difference was
noted between the groups for 6-month changes in insulin
Figure 1 Correlation between 3-month changes in IGF-1 and
body fat percentage within the rhGH treated group. 3-month
increase in IGF-1 was associated with the 3-month decrease in %
body fat.
Figure 2 Correlation of 6-month change in IGF-1 with 6-month
change in total cholesterol for all subjects. 6-month increase in
IGF-1 was associated with the 6-month decrease in total cholesterol.
Figure 3 Change in soluble intercellular adhesion molecule-1
(sICAM) levels in obese adolescent females. Change in sICAM
levels in obese adolescent females after 6 months of recombinant
human growth hormone therapy (rhGH +) (black bar) or placebo/no
treatment (rhGH -) (gray bar).
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effects of rhGH on glucose tolerance.
Adverse events over the 6-month study duration
Adverse events are presented in Table 3. There were no
serious adverse events related to study participation.
rhGH was well tolerated and no subject required a dose
reduction. No subject who complained of headaches,
nausea or vomiting had a history or physical exam findings
suggestive of pseudotumor cerebri.
Discussion
We have shown that administering rhGH to female ado-
lescents in physiologic doses is able to stabilize IGF-1 in
obesity, a state characterized by relative GH insufficiency,
without adversely affecting glucose tolerance. We also
confirmed the lipolytic effects of endogenous rhGH,
administered for the first time to otherwise healthy obese
adolescent females, resulting in a decrease in total choles-
terol; additionally, we saw a reduction in sICAM-1 as
opposed to an increase in sICAM-1 levels in the non-
intervention group. Our group has previously reported a
relative state of GH insufficiency in obese adolescent girls
compared with controls, and that lower GH levels strongly
predict higher visceral fat, an important determinant of
insulin resistance and hyperlipidemia [3]. Although GH
replacement causes a decrease in visceral adiposity in GH
deficient children [13], effects of GH administration on body
composition and cardiometabolic risk have not been previ-
ously examined in a healthy adolescent obese population.
Despite small increases in IGF-1, the dose of rhGH used
in our study achieved significant reductions in total chol-
esterol and sICAM-1. It is thus possible that observed
changes represent direct lipolytic effects of GH and direct
effects of GH on inflammatory markers, rather than IGF-1
mediated effects. However, we did observe significant in-
verse associations between 6-month changes in IGF-1
levels and 6-month changes in total cholesterol, triglycer-
ides, and VLDL. Although we observed a decrease in
HDL levels in the active arm, no correlation was found
Table 3 Adverse events in treated obese girls (rhGH+)
and untreated obese girls (rhGH -)
Event type Total number
of adverse events
Adverse events
RhGH+(N) RhGH - (N)
Serious adverse
events
-- -
Non-serious
adverse events
Hyperglycemia
related events
IGT at 3 or 6-month
(OGTT)
62 4
Polyuria/Polydipsia 4 3 1
HbA1c>6.4% 1 1 -
Symptoms that may
relate to raised ICP
Headache 7 4 3
Nausea with
vomiting
11 -
Nausea without
vomiting
33 -
Dizziness without
headache
1- 1
Blurry vision 1 1 -
Arthralgias/Fluid
retention related
events
Arthralgia 2 2 -
Back pain 5 4 1
Myalgia 1 1 -
Edema - - -
Menstrual cycle
related events
Change in
menstrual Flow
53 2
Injection related
events
Bruising/Irritation at
injection site
42 2
Bruising/Irritation at
blood sampling site
11 -
Others
Hypertension 1 - 1
Lightheadedness - - -
ED visit for
wheezing with URI
1- 1
Abdominal pain 2 2 -
Upper respiratory
Infection
11 -
Table 3 Adverse events in treated obese girls (rhGH+)
and untreated obese girls (rhGH -) (Continued)
Nasal congestion
(with URI)
11 -
Fatigue 2 - 2
Eczema 1 - 1
RhGH+: Group that received rhGH; RhGH-: Group that received
placebo/no treatment.
Abbreviations: ED emergency department, ICP intracranial pressure,
IGT impaired glucose tolerance, OGTT oral glucose tolerance test, URI upper
respiratory infection.
There were no significant differences across the two groups for the various
adverse events.
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Of note, by the end of puberty, the increase in insulin
resistance that is characteristic of puberty resolves, and
returns to prepubertal levels [23]. All subjects in our study
were fully pubertal at the start of the study, thus any
puberty related variations in insulin resistance parameters
were minimized. We speculate that the decrease in sICAM
levels in the active arm compared with the increase in the
non-treatment arm may represent reduced inflammation in
the active arm, compared to a persistent (and potentially
worsening) pro-inflammatory state in the non-treatment
arm. This may account for the maintenance of HbA1C
levels in the intervention group, as opposed to the increase
in HbA1C observed over 6 months in the non-intervention
group. Given that rhGH studies in adults have found that
even at low doses, GH treatment corresponds with elevated
glucose and insulin levels [5], adolescence may potentially
offer a time period when rhGH replacement (in doses used
in this study) will not worsen glucose tolerance.
Given the known inverse associations of GH levels
with VAT and hsCRP in obesity, [3,24,25] we expected to
see a reduction in VAT content and in hsCRP levels
following rhGH administration. However, contrary to
our expectations, neither of these parameters decreased,
and it is possible that higher doses of rhGH than
achieved in this study are necessary to observe such an
effect. Following rhGH administration, although the
mean IGF-1 level attained in the active arm was higher
than in the control arm, this was not statistically signifi-
cant, and mean levels remained in the lower half of the
normal range despite dose titration. Thus, a state of relative
GH insufficiency persisted. It is unclear why IGF-1 de-
creased in the control group. Although variation within the
IGF-1 range is an expected finding, it is also possible that
the non-significant weight gain in the control group over
6 months contributed to a decrease in GH, and therefore,
IGF-1 secretion [3,24,25].
We did observe inverse associations of changes in IGF-1
with changes in the waist/hip ratio, considered to be an
excellent surrogate for VAT, which also suggests that a
higher dosage of rhGH may have caused improvements in
body composition and biochemical parameters overall.
The fact that glucose tolerance did not deteriorate in the
active arm may also be attributable to the low dosage of
rhGH used in the active arm [24,26]. Further studies are
necessary based on data from this proof-of-concept study
to determine the most appropriate dose of rhGH to
improve body composition and cardiometabolic risk
markers in obese adolescent girls without significantly
worsening insulin resistance.
Limitations of this study include the small sample size
and relatively high drop-out rate (common in studies
with obese subjects) [27-29]. However, a significant
strength was that we observed changes in lipids and an
inflammatory marker despite the small sample size and
low GH dose. Many previous studies examining the
relationship between IGF-1 and body composition limited
their findings to BMI [30,31] and previous prospective
rhGH treatment studies focused on obese adults [2,24,25].
The remaining studies that either prospectively or retro-
spectively analyzed the effects of rhGH on body compos-
i t i o ni nt h ep e d i a t r i cp o p u l a t i o ni n v o l v e dc h i l d r e nw i t h
Prader-Willi syndrome or GH deficiency [13,14,32]. This
current study is the first to examine the effects of rhGH on
otherwise healthy obese adolescents.
Conclusions
In conclusion, we have demonstrated that low rhGH doses
are easily tolerated with minimal side effects and are able
to stabilize IGF-1 levels in obese adolescent girls. Our
study confirms the lipolytic effects of growth hormone and
suggests that rhGH replacement in viscerally obese adoles-
cent females reduces total cholesterol and sICAM without
adversely affecting glycemic status. Further studies are
necessary to confirm these findings, and to also better
understand the potential clinical role of rhGH as a treat-
ment for obese adolescent girls.
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